Publications by authors named "C Handforth"
Introduction: SCLC is characterized by aggressiveness and limited treatment options, especially in extensive-stage SCLC (ES-SCLC). Immunotherapy added to the platinum-etoposide combination has recently become standard in this setting. This retrospective study aims to evaluate the real-world effectiveness of chemo-immunotherapy in patients with ES-SCLC, focusing on subpopulations excluded from clinical trials.
View Article and Find Full Text PDFBackground: There is interest in using treatment breaks in oncology, to reduce toxicity without compromising efficacy.
Trial Design: A Phase II/III multicentre, open-label, parallel-group, randomised controlled non-inferiority trial assessing treatment breaks in patients with renal cell carcinoma.
Methods: Patients with locally advanced or metastatic renal cell carcinoma, starting tyrosine kinase inhibitor as first-line treatment at United Kingdom National Health Service hospitals.
Introduction: Androgen Deprivation Therapy (ADT) for prostate cancer (PC) has substantial negative impacts on the musculoskeletal system and body composition. Many studies have focused on the effects of ADT on areal bone mineral density (aBMD), but aBMD does not capture key determinants of bone strength and fracture risk, for example volumetric bone density (vBMD), geometry, cortical thickness and porosity, trabecular parameters and rate of remodelling. More specialist imaging techniques such as high-resolution peripheral quantitative computed tomography (HR-pQCT) have become available to evaluate these parameters.
View Article and Find Full Text PDFArticle Synopsis
- - Older and frail patients are often excluded from major cancer studies, creating a need for specialized research, such as the GO2 trial focused on adjusting chemotherapy for this population in advanced gastroesophageal cancer.
- - The trial had two randomization groups: one comparing different levels of chemotherapy intensity and another comparing best supportive care to a lower chemotherapy dose if treatment uncertainty arose.
- - Results showed that 514 patients were recruited, primarily men with a median age of 76, and confirmed that lower doses of chemotherapy (Level B) were noninferior in terms of progression-free survival compared to standard doses (Level A).